Effect of “In Use” Administration on Topical Product Metamorphosis and Skin Permeation of Acyclovir Creams: Implications for Bioequivalence
Pharmaceutical Research · 2024
DOI: 10.1007/s11095-024-03797-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Sarika N Namjoshi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutics Research Centre, Frazer Institute, Translational Research Institute, Woolloongabba, QLD, Australia. Hauptthemen laut MEDLINE: Acyclovir, Skin Absorption, Skin Cream, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Center for Drug Evaluation and Research.
Abstract (Originalsprache)
PURPOSE: Typical clinical "in use" conditions for topical semisolids involve their application as a thin film, often with rubbing that can induce metamorphic stress. Yet, product quality and performance tests often characterize the manufactured product, and may not consider product metamorphosis (e.g., shear history) during dispensing and administration. This work sought to elucidate how such metamorphosis might alter product quality and performance. METHODS: We evaluated the effect of "in use" stresses on drug crystal metamorphosis in acyclovir creams by optical microscopy. The amount of dissolved acyclovir was determined by separation of the cream base by ultra-centrifugation and quantification by HPLC. IVPT was undertaken on Zovirax® US and Aciclostad® comparing static and "in use" application of a finite dose. A mechanistic IVPT study was also conducted to understand the influence of acyclovir particle size reduction by "in use" rubbing on skin permeation. RESULTS: Reduction in acyclovir particle size was seen after "in use" rubbing with increases in the amount of dissolved acyclovir after rubbing (30 and 60 s) compared to static for both products. "In use" application resulted in significantly higher acyclovir permeation from both products. The mechanistic IVPT study proved the role of product metamorphosis. CONCLUSION: These results highlight the role of metamorphosis of product microstructure and its influence on performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Therapeutics Research Centre, Frazer Institute, Translational Research Institute, Woolloongabba, QLD, Australia.
- Curtin Medical School, Curtin University, Perth, WA, Australia.
- Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.
- Therapeutic Research Centre, Basil Hetzel Institute for Translational Medical Research, The Queen Elizabeth Hospital, Adelaide, SA, Australia.
- Therapeutics Research Centre, Frazer Institute, Translational Research Institute, Woolloongabba, QLD, Australia. y.mohammed@uq.edu.au.
Förderung
- Center for Drug Evaluation and Research
Zitieren
APA
Namjoshi, S. N., Telaprolu, K. C., Grice, J. E., Benson, H. A. E., Raney, S. G., Roberts, M. S., & Mohammed, Y. H. (2024). Effect of “In Use” Administration on Topical Product Metamorphosis and Skin Permeation of Acyclovir Creams: Implications for Bioequivalence. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03797-w
Vancouver
Namjoshi SN, Telaprolu KC, Grice JE, Benson HAE, Raney SG, Roberts MS, et al. Effect of “In Use” Administration on Topical Product Metamorphosis and Skin Permeation of Acyclovir Creams: Implications for Bioequivalence. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03797-w
BibTeX
@article{Namjoshi2024,
author = {Namjoshi, Sarika N and Telaprolu, K C and Grice, Jeffrey E and Benson, Heather A E and Raney, S G and Roberts, Michael S and Mohammed, Yousuf H},
title = {Effect of “In Use” Administration on Topical Product Metamorphosis and Skin Permeation of Acyclovir Creams: Implications for Bioequivalence},
journal = {Pharmaceutical Research},
year = {2024},
doi = {10.1007/s11095-024-03797-w}
}
EUVIMED